Gilead Prices Covid-19 Drug Candidate Remdesivir at $2,340 Per Patient in US

Gilead has entered into an agreement with the U.S. Department of Health and Human Services (HHS) whereby the department and states will manage allocation to hospitals until September end.

Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.